GSK Global strengthens commitment with US $ 11 million FDI

GlaxoSmithKline (GSK) infused a foreign direct investment of $ 11 million to further expand its operations in Sri Lanka.

T. S. Dayanand, Managing Director of GSK Consumer Healthcare said, "Over the years, we have consistently invested in the Sri Lankan business. This new investment will enable us to bring more new products to our consumers. It will also help us localise more of our products and reduce dependence on imports."

GSK's legacy in Sri Lanka extends over 60 years. The company touches the lives of millions around the country through its trusted consumer healthcare brands such as Panadol, Viva, Horlicks, Iodex, Eno, Sensodyne and leading pharmaceutical products.

Promoting local manufacture, earlier this year GSK Sri Lanka inaugurated a new state-of-the-art tablet manufacturing facility in Ratmalana. The new facility was the result of a Rs 217 million investment - one of the single largest investments in the Sri Lankan pharmaceutical industry. This aims to strengthen local operations and uplift the pharmaceutical manufacturing capability while saving the country precious foreign exchange.

Currently employing over 500 employees directly and indirectly, GSK also works with 70 distributors. This enables wide access of GSK's products to the people of Sri Lanka.

On a mission "To improve the quality of human life by enabling people to do more, feel better and live longer," GlaxoSmithKline continues to further the well-being of Sri Lankans through research into new medicines and innovative healthcare products and support the development goals of the country through meaningful investments.